News and Events

Lead Pharma Participant in BIOCDx EU project

A miniature Bio-photonics Companion Diagnostics platform for reliable cancer diagnosis and treatment monitoring.

BIOCDx project is an initiative funded by the European Union under the H2020 Programme, aiming to provide a Point-of-Care (PoC) device for early cancer diagnosis and treatment monitoring. Read more

 

 

Lead Pharma Achieves Second Milestone for Development of Autoimmune Diseases Treatments in Sanofi Collaboration     - Company receives undisclosed second milestone payment. 

Nijmegen, February 27, 2017 -Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of autoimmune diseases and cancer, today announced that it has achieved a second milestone under its research collaboration with Sanofi, triggering an undisclosed milestone payment. The collaboration aims to develop small molecules directed against the nuclear hormone receptor ROR gamma (t) for the treatment of a broad range of autoimmune disorders, including common diseases such as rheumatoid arthritis and inflammatory bowel disease. Read More

 

 

Lead Pharma Achieves first Milestone for Development of Autoimmune Diseases Treatments in Research  Collaboration with Sanofi.- Company receives undisclosed milestone payment.

Nijmegen, November 2, 2015 - Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of autoimmune diseases and cancer, today announced that it has achieved the first milestone under its research collaboration with Sanofi, triggering an undisclosed milestone payment. The collaboration aims to develop small molecules directed against the nuclear hormone receptor ROR gamma (t) for the treatment of a broad range of autoimmune disorders, including common diseases such as rheumatoid arthritis and inflammatory bowel disease. Read more

 

Lead Pharma Appoints Three Seasoned Industry Experts to its Supervisory Board   - Jan Egberts, M.D., Ir. Jan van der Hoeven and Daan van den Noort, M.D. join newly established Supervisory Board

Nijmegen, June 18,2015 -Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of autoimmune diseases and cancer, today announced that it has appointed Dr. Jan Egberts, Ir. Jan van der Hoeven and Daan van den Noort to its newly established Supervisory Board. Read more


 

Lead Pharma to Partner with Sanofi on Development of Treatments for Autoimmune Diseases
- R&D collaboration and license agreement may yield potential first-in-class oral anti-ROR gamma (t) therapies

Nijmegen, Feb. 18, 2015 - Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of autoimmune diseases and cancer, today announced that it has entered into a research collaboration and license agreement with Sanofi to discover, develop and commercialize small molecule therapies directed against the nuclear hormone receptor ROR gamma (t) to treat a broad range of autoimmune disorders, including common diseases such as rheumatoid arthritis and inflammatory bowel disease. Read more

 

Upcoming events: